Question 1

What is Switzerland — Innosuisse?

Accepted Answer

Switzerland — Innosuisse is a Entity.

Question 2

How often does Switzerland — Innosuisse appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 13 articles.

Question 3

When was Switzerland — Innosuisse first tracked by Ergen?

Accepted Answer

First tracked on Apr 24, 2026.

Question 4

When was Switzerland — Innosuisse last mentioned in news?

Accepted Answer

Last active on Jul 01, 2026.

Question 5

What is Switzerland — Innosuisse's current news sentiment?

Accepted Answer

Aggregate sentiment score: 25 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Switzerland — Innosuisse in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Switzerland — Innosuisse?

Accepted Answer

MindMaze Therapeutics European Reimbursement Studies (Jul 01, 2026, 6 articles).

Question 8

How did the "MindMaze Therapeutics European Reimbursement Studies" event impact Switzerland — Innosuisse?

Accepted Answer

Switzerland — Innosuisse is funding the SwissNeuroRehab consortium with CHF 11.2 million, supporting the development and validation of technology-supported neurorehabilitation pathways in Switzerland.

Question 9

How did the "Gain Therapeutics Presents GT-02287 Update" event impact Switzerland — Innosuisse?

Accepted Answer

Switzerland — Innosuisse - Swiss Innovation Agency co-funded the Eurostar joint program, which supported Gain Therapeutics' Parkinson s disease program.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.